Monopar Therapeutics (MNPR): R&D Expense
$9.90M
Year ended 2025-12-31
$14.78M
Trailing 12 months to 2026-06-30
+9.3%
3-year compound annual growth
+19.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.90M | -23.8% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $13.01M | +132.2% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $5.60M | -26.2% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $7.59M | +16.9% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $6.49M | +59.7% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $4.07M | +106.5% | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | $1.97M | +10.9% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $1.77M | +89.7% | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | $935.3K | +233.6% | 2019-02-26, From 2017-01-01 |
| 2016-12-31 | $280.4K | n/a | 2018-03-26, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | 2025-12-31 | $9.90M | -23.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare MNPR, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗